Global Antibiotic R&D Partnership (GARDP)
Capucine Robert is a Clinical Trial Associate at the Global Antibiotic R&D Partnership (GARDP) since December 2022, contributing to a phase 3 study in sexually transmitted infections. Prior to this role, Capucine served as an Associate Clinical Trial Manager at ObsEva SA, managing phase III studies in obstetrics across the EU and US from June 2019 to November 2022. Previous experience includes a traineeship as a Research Collaborator at CHUV in the Oncology Department, an Instrument Validation Engineer role at Quotient Limited, and various positions within Merck Group, Novartis Consumer Health, Vifor Pharma, and Celgene focusing on quality control, analytical development, and research. Capucine's educational background includes a clinical research training at CHUV and a master's degree in chemistry from the University of Sciences and Technologies of Franche Comté, complemented by ongoing coursework through Coursera.
Global Antibiotic R&D Partnership (GARDP)
The Global Antibiotic Research & Development Partnership (GARDP) is a not-for-profit organization that develops new antibiotic treatments for drug-resistant bacterial infections that pose the greatest threat to human health, and makes them accessible to the people who need them. It puts public health needs at the centre of antibiotic drug development to address both the immediate antimicrobial resistance (AMR) crisis and to ensure people continue to get access to essential antibiotics for generations to come. GARDP works through a global network including Brazil, India, Japan, and South Africa for antibiotic development and access. Its work is made possible by essential funding from donors and collaboration with over 100 R&D and access partners in over 20 countries. GARDP was created by the World Health Organization and the Drugs for Neglected Diseases initiative (DNDi) in 2016 and legally registered as the GARDP Foundation in Geneva, Switzerland in 2018. www.gardp.org